AFFAMED THERAPEUTICS
AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products.
AFFAMED THERAPEUTICS
Social Links:
Industry:
Biotechnology
Founded:
2019-01-01
Address:
New City, New York, United States
Country:
United States
Total Employee:
101+
Status:
Active
Total Funding:
170 M USD
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-10-14 | EverInsight Therapeutics | EverInsight Therapeutics acquired by AffaMed Therapeutics | N/A |
Investors List
Orion Capital Group, Inc.
Orion Capital Group, Inc. investment in Series B - AffaMed Therapeutics
CBC Investment Group
CBC Investment Group investment in Series B - AffaMed Therapeutics
Fountainhead Investment Partners
Fountainhead Investment Partners investment in Series B - AffaMed Therapeutics
Lake Bleu Capital
Lake Bleu Capital investment in Series B - AffaMed Therapeutics
Partners Investment
Partners Investment investment in Series B - AffaMed Therapeutics
Superstring Capital
Superstring Capital investment in Series B - AffaMed Therapeutics
More informations about "AffaMed Therapeutics"
AffaMed蔼睦医疗
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet …See details»
AffaMed Therapeutics 2025 Company Profile: …
AffaMed Therapeutics’s most recent deal was a Joint Venture with AffaMed Therapeutics & SIFI (Joint Venture) for . The deal was made on 31-Mar-2021. …See details»
AffaMed Therapeutics - Funding, Financials, Valuation & Investors
Oct 14, 2020 AffaMed Therapeutics is funded by 6 investors. C-Bridge Capital and Orion Capital Group, Inc. are the most recent investors. AffaMed Therapeutics has acquired EverInsight …See details»
Affamed Therapeutics (Us), Inc. - Drug pipelines, Patents, Clinical ...
Before Mineralys, she held the same role at Affamed Therapeutics and has past experience at Jounce Therapeutics, Curis and Hoffmann-La Roche. Release > ProMIS Neurosciences is …See details»
Leadership-AffaMed蔼睦医疗
沪 ICP 备 2021003460-1 ©2021 AffaMed Therapeutics ：31010602006246 ... Ms. Jiang served as Director and COO at Far East Horizon’s Investments Group, a financial services …See details»
AffaMed Therapeutics Company Profile | Management and
AffaMed Therapeutics Profile and History. AffaMed Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing transformative …See details»
Affamed - Digital Therapeutics Alliance
AffaMed Digital is a wholly-owned subsidiary of AffaMed Therapeutics, dedicated to develop and commercialize evidence-based, clinically evaluated digital therapeutics and diagnosis systems for ophthalmic, neurological, and …See details»
AffaMed Therapeutics (US) Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AffaMed Therapeutics (US) Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
AffaMed Therapeutics - Contacts, Employees, Board Members
AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products. ... Experience the new Crunchbase, …See details»
AffaMed Therapeutics Announces Completion of over US$170 …
Mar 30, 2021 AffaMed Therapeutics was founded and funded by the CBC Group in 2019. About Lake Bleu Capital. Based in Hong Kong and Shanghai, Lake Bleu Capital (www.lakebleu …See details»
AffaMed Therapeutics Company Overview, Contact Details
Mar 30, 2021 AffaMed Therapeutics. Biotechnology Research Shanghai, China 51-200 Employees. AffaMed Therapeutics is a clinical stage therapeutic company focused on …See details»
AffaMed - Company Profile - Tracxn
Jan 12, 2025 AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and …See details»
AffaMed Therapeutics Announces Merger with EverInsight …
Oct 14, 2020 He was also head of the Development China organization, which is responsible for all clinical development in China for the global markets. ... AffaMed Therapeutics was founded …See details»
AffaMed Therapeutics Announces Clinical Trial Application …
Sep 25, 2023 AffaMed Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical, digital and surgical products …See details»
AffaMed Therapeutics Announces Merger with EverInsight …
Oct 14, 2020 About AffaMed Therapeutics AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products …See details»
AffaMed Therapeutics Announces Completion of over US$170 …
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in …See details»
Series B - AffaMed Therapeutics - 2021-03-30 - Crunchbase
Organization Name . AffaMed Therapeutics . Announced Date Mar 30, 2021; Funding Type Series B; Funding Stage Early Stage Venture; Money Raised . obfuscated. obfuscated. Lead …See details»
AffaMed Therapeutics Announces Clinical Trial Application …
Sep 25, 2023 AffaMed Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical, digital and surgical products …See details»
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve …
AffaMed Therapeutics was founded and funded by the CBC Group in 2019. About SIFI . SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI …See details»
Abelacimab: the next frontier in safer anticoagulation therapy
5 days ago The landscape of anticoagulation therapy could be on the brink of a major transformation. In an interview with Dr. Dan Bloomfield, Cardiologist and CMO at Anthos …See details»